In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer: Innovation at the Lowest Cost

Executive Summary

Pfizer's economic figuring goes something like this: an internally discovered drug, or one licensed for relatively little money at an early stage of development, can nonetheless be considerably less profitable than one in-licensed when it is nearly ready for NDA filing, even if the drug costs a small fortune in cash and quids.
Advertisement

Related Content

Ironwood Pharmaceuticals: Independent for the Long Haul
Ironwood Pharmaceuticals: Independent for the Long Haul
Canary in the Coalmine: Pfizer R&D
Pfizer R&D: The Biggest Pharmaceutical Experiment
Pfizer R&D: The Biggest Pharmaceutical Experiment
Pfizer's Balancing Act

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV000453

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel